Emerging migraine treatments and drug targets

Trends in Pharmacological Sciences

Volumn 32, Issue 6, 2011, Pages 352-359

  Olesen, Jes ^a   Ashina, Messoud ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADX 10059; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BI 44370 TA; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CANNABINOID; GLUTAMATE RECEPTOR ANTAGONIST; KETAMINE; LASMIDITAN; NITRIC OXIDE ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OLCEGEPANT; ONABOTULINUMTOXIN A; OREXIN; PLACEBO; PROSTAGLANDIN E RECEPTOR 2 ANTAGONIST; PROSTAGLANDIN E RECEPTOR 4 ANTAGONIST; SEROTONIN 1 AGONIST; SEROTONIN 1D AGONIST; SEROTONIN AGONIST; SPIEGELMER; SUMATRIPTAN; TELCAGEPANT; TONABERSAT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST;

CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC SYSTEM; CONCENTRATION LOSS; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FAMILIAL HEMIPLEGIC MIGRAINE; HEMIPLEGIC MIGRAINE; HUMAN; HYPERTRANSAMINASEMIA; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SPREADING CORTICAL DEPRESSION; TENSION HEADACHE; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

BENZAMIDES; BENZOPYRANS; BOTULINUM TOXINS, TYPE A; DRUG DESIGN; DRUG THERAPY; HUMANS; MIGRAINE DISORDERS; NERVOUS SYSTEM; NITRIC OXIDE; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN;

EID: 79957762234     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.02.016     Document Type: Review

References (93)

1. Rasmussen, B.K. et al. (1991) Epidemiology of headache in a general population - a prevalence study. J. Clin. Epidemiol. 44, 1147-1157
2. Stovner, L. et al. (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27, 193-210 (Pubitemid 46354128)
3. Rasmussen, B.K. et al. (1992) Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J. Epidemiol. Community Health 46, 443-446
4. Lyngberg, A.C. et al. (2005) Secular changes in health care utilization and work absence for migraine and tension-type headache: a population based study. Eur. J. Epidemiol. 20, 1007-1014
5. Andlin-Sobocki, P. et al. (2005) Cost of disorders of the brain in Europe. Eur. J. Neurol. 12, 1-27
6. Stovner, L.J. and Andree, C. (2008) Impact of headache in Europe: a review for the Eurolight project. J. Headache Pain 9, 139-146
7. Hu, X.H. et al. (1999) Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 159, 813-818
8. Olesen, J. et al. (2009) Finding new drug targets for the treatment of migraine attacks. Cephalalgia 29, 909-920
9. Olesen, J. et al. (2009) Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 8, 679-690
10. Goadsby, P.J. et al. (2009) Neurobiology of migraine. Neuroscience 161, 327-341
11. de Vries, B. et al. (2009) Molecular genetics of migraine. Hum. Genet. 126, 115-132
12. Anttila, V. et al. (2010) Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat. Genet. 42, 869-873
13. Johnston, M.M. and Rapoport, A.M. (2010) Triptans for the management of migraine. Drugs 70, 1505-1518
14. 1F receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics 7, 176-182
15. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668-1675
16. Villalon, C.M. et al. (2002) An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc. West Pharmacol. Soc. 45, 199-210
17. Nelson, D.L. et al. (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30, 1159-1169
18. Ferrari, M.D. et al. (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - a randomised proof-of-concept trial. Cephalalgia 30, 1170-1178
19. Uddman, R. et al. (1985) Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci. Lett. 62, 131-136
20. Uddman, R. et al. (1986) Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul. Pept. 15, 1-23
21. Edvinsson, L. et al. (1985) Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci. Lett. 58, 213-217
22. Lassen, L.H. et al. (2002) CGRP may play a causative role in migraine. Cephalalgia 22, 54-61 (Pubitemid 34626025)
23. Hansen, J.M. et al. (2010) Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30, 1179-1186
24. Villalon, C.M. and Olesen, J. (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol. Ther. 124, 309-323
25. Olesen, J. et al. (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104-1110
26. Ho, T.W. et al. (2008) Randomized controlled trial of an oral CGRP receptor antagonist MK-0974, in acute treatment of migraine. Neurology 70, 1304-1312 (Pubitemid 351550355)
27. Ho, T.W. et al. (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372, 2115-2123
28. Connor, K.M. et al. (2009) Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73, 970-977
29. Diener, H.C. et al. (2010) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a Phase II study. Cephalalgia DOI: 10.1177/0333102410388435
30. Iversen, H.K. et al. (1989) Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 38, 17-24 (Pubitemid 19184833)
31. Thomsen, L.L. et al. (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur. Neurol. 1, 73-80
32. Olesen, J. (2010) Nitric oxide-related drug targets in headache. Neurotherapeutics 7, 183-190
33. Griffith, O.W. and Kilbourn, R.G. (1996) Nitric oxide synthase inhibitors: amino acids. Methods Enzymol. 268, 375-392 (Pubitemid 26286380)
34. Lassen, L.H. et al. (1998) Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 18, 27-32 (Pubitemid 28096515)
35. Høivik, H.O., Laurijssens, B.E., Harnisch, L.O., Twomey, C.K., Dixon, R.M., Kirkham, A.J., Williams, P.M., Wentz, A.L. and Lunnon, M.W. (2010) Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30, 1458-1467
36. Hoivik, H.O. et al. (2010) Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30, 1458-1467
37. Saxena, P.R. and Tfelt-Hansen, P. (2006) Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraines, In The Headaches (3rd edn) (Olesen, J. et al., eds), pp. 469-503, Lippincott Williams & Wilkins
38. Brandes, J.L. et al. (2009) Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 49, 1435-1444
39. Rapoport, A.M. (2010) New acute treatments for headache. Neurol. Sci. 31, S129-S132
40. Shrewsbury, S.B. et al. (2008) Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo) inhaler. Headache 48, 355-367 (Pubitemid 351517766)
41. Aurora, S.K. et al. (2009) A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 49, 826-837
42. Kaube, H. et al. (2000) Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55, 139-141 (Pubitemid 30461018)
43. Evers, S. et al. (2006) EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur. J. Neurol. 13, 560-572
44. Evers, S. (2006) Status on the use of botulinum toxin for headache disorders. Curr. Opin. Neurol. 19, 310-315
45. Aurora, S.K. et al. (2010) Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30, 793-803
46. Diener, H.C. et al. (2010) Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30, 804-814
47. Mathew, N.T. et al. (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45, 293-307 (Pubitemid 40530193)
48. Hadjikhani, N. et al. (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl. Acad. Sci. U.S.A. 98, 4687-4692
49. Olesen, J. et al. (1981) Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann. Neurol. 9, 344-352
50. Lauritzen, M. and Olesen, J. (1984) Regional cerebral blood flow during migraine attacks by xenon-133 inhalation and emission tomography. Brain 107 (Pt 2), 447-461 (Pubitemid 14108830)
51. Damodaram, S. et al. (2009) Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Headache 49, 5-20
52. Read, S.J. et al. (2000) SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 20, 92-99 (Pubitemid 32269515)
53. Goadsby, P.J. et al. (2009) Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 29, 742-750
54. Hauge, A.W. et al. (2009) Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 8, 718-723
55. Marin, J.C. and Goadsby, P.J. (2010) Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Expert. Opin. Investig. Drugs 19, 555-561
56. Olesen, J. et al. (1993) Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 4, 1027-1030 (Pubitemid 23242637)
57. Lassen, L.H. et al. (1997) Nitric oxide synthase inhibition in migraine. Lancet 8, 401-402 (Pubitemid 27077677)
58. Lassen, L.H. et al. (1995) Histamine induces migraine via the H1-receptor Support for the NO hypothesis of migraine. Neuroreport 6, 1475-1479
59. Birk, S. et al. (2005) The effect of circulating adenosine on cerebral haemodynamics and headache generation in healthy subjects. Cephalalgia 25, 369-377 (Pubitemid 40559419)
60. Schytz, H.W. et al. (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132, 16-25
61. Petersen, K.A. et al. (2009) Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia 29, 23-30
62. Wienecke, T. et al. (2010) Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 30, 179-190
63. Kruuse, C. et al. (2003) Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126, 241-247 (Pubitemid 36068573)
64. Birk, S. et al. (2006) The headache-inducing effect of cilostazol in human volunteers. Cephalalgia 26, 1304-1309 (Pubitemid 44625681)
65. Schytz, H.W. et al. (2010) Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura. Cephalalgia 30, 337-345
66. Saxena, P.R. (2008) New 5-hydroxytryptamine-related drug targets. In Innovative Drug Development for Headache Disorders (Olesen, J. and Ramadan, N.M., eds), pp. 109-114, Oxford University Press
67. 8-37, a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br. J. Pharmacol. 150, 633-640
68. Schytz, H.W. et al. (2010) What have we learnt from triggering migraine? Curr. Opin. Neurol. 23, 259-265
69. Hansen, J.M. et al. (2006)Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 26, 992-1003 (Pubitemid 44079724)
70. Rahmann, A. et al. (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28, 226-236 (Pubitemid 351172031)
71. Harmar, A.J. et al. (1998) International Union of Pharmacology XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50, 265-270
72. Schytz, H.W. et al. (2010) The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics 7, 191-196
73. Tfelt-Hansen, P. and Rolan, P. (2006) Nonsteroidal anti-inflammatory drugs in the acute treatment of migraine, In The Headaches (3rd edn) (Olesen, J. et al., eds), pp. 449-457, Lippincott Williams & Wilkins
74. Evers, S. and Mylecharane, E.J. (2006) Nonsteroidal antiinflammatory and miscellaneous drugs in migraine prophylaxis, In The Headaches (3rd edn) (Olesen, J. et al., eds), pp. 553-565, Lippincott Williams & Wilkins
75. Wienecke, T. et al. (2008) Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 139, 106-116
76. Wienecke, T. et al. (2009) Prostaglandin E2 (PGE2) induces headache in healthy subjects. Cephalalgia 29, 509-519
77. Karczmar, A.G. (1993) Brief presentation of the story and present status of studies of the vertebrate cholinergic system. Neuropsychopharmacology 9, 181-199
78. Burstein, R. and Jakubowski, M. (2005) Unitary hypothesis for multiple triggers of the pain and strain of migraine. J. Comp. Neurol. 493, 9-14
79. Schytz, H.W. et al. (2009) The cholinomimetic agent carbachol induces headache in healthy subjects. Cephalalgia 29, 258-268
80. Bartsch, T. et al. (2004) Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 109, 367-378 (Pubitemid 38638714)
81. Holland, P.R. et al. (2005) Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J. Pharmacol. Exp. Ther. 315, 1380-1385
82. Holland, P.R. et al. (2006) Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur. J. Neurosci. 24, 2825-2833
83. Guindon, J. and Hohmann, A.G. (2009) The endocannabinoid system and pain. CNS Neurol. Disord. Drug Targets 8, 403-421
84. Greco, R. et al. (2010) The endocannabinoid system and migraine. Exp. Neurol. 224, 85-91
85. Jansen-Olesen, I. et al. (1996)Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16, 310-316 (Pubitemid 26271251)
86. Ho, T.W. et al. (2008) Randomized controlled trial of an oral CGRP antagonist MK-0974, in acute treatment of migraine. Neurology 70, 1304-1312 (Pubitemid 351550355)
87. Voight, E.A. and Kort, M.E. (2010) Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature. Expert Opin. Ther. Pat. 20, 1107-1122
88. van den Maagdenberg, A.M. et al. (2007) Migraine: gene mutations and functional consequences. Curr. Opin. Neurol. 20, 299-305
89. Gozalov, A. et al. (2005) Role of K ATP channels in the regulation of rat dura and pia artery diameter. Cephalalgia 25, 249-260 (Pubitemid 40445809)
90. Gozalov, A. et al. (2008) Role of KATP channels in cephalic vasodilatation induced by calcitonin gene-related peptide, nitric oxide, and transcranial electrical stimulation in the rat. Headache 48, 1202-1213
91. Ploug, K.B. et al. (2010) Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. Eur. J. Pharmacol. 637, 109-117
92. Storer, R.J. et al. (2009) Large conductance calcium-activated potassium channels (BKCa) modulate trigeminovascular nociceptive transmission. Cephalalgia 29, 1242-1258
93. Gozalov, A. et al. (2007) Role of BKCa channels in cephalic vasodilation induced by CGRPNOand transcranial electrical stimulation in the rat. Cephalalgia 27, 1120-1127 (Pubitemid 47476138)